|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Site-specific pharmaco-laser therapy:A novel treatment modality for refractory port wine stains显示文摘Despite extensive efforts to optimize laser therapy,i.e.,the current gold standard treatment,a majority of port wine stain(PWS)patients responds suboptimally to laser therapy.This paper describes the niceties of a novel PWS treatment modality termed site-specific pharmaco-laser therapy(SSPLT).In contrast to the classic approach of enhancing the extent of intravascular photocoagulation(the photothermal response),SSPLT focuses on optimization of post-irradiation thrombus formation(i.e.,the hemodynamic response)by combining conventional laser therapy with the administration of thermosensitive drug delivery systems that encapsulate prothrombotic and antifibrinolytic drugs.The aim of SSPLT is to instill complete lumenal occlusion in target vessels,which has been linked to optimal PWS blanching.Relevance for patients:The current treatment options for PWS patients are limited in efficacy.Novel therapeutic modalities are needed to more effectively treat patients with recalcitrant PWSs.SSPLT is an experimental-stage treatment modality that could serve as an adjuvant to pulsed dye laser therapy for a selected group of patients whose PWS is ill-responsive to standard treatment.The expected clinical result of SSPLT is improved lesional blanching. | M.Ingmar van Raath Jojanneke E.van Amesfoort Martin Hermann Yasin Ince Maurice J.Zwart Agustina V.Echague Yan Chen Baoyue Ding Xuan Huang Gert Storm Michal Heger | 2019 | Journal of Clinical & Translational Research2019，5，1： | 4 |
| 2 | Potential therapeutic benefits stemming from the thermal nature of irreversible electropora tion of solid cancers显示文摘To the Editor:Irreversible electroporation(IRE)is a CE-and FDAapproved treatment modality for pancreatic and liver tumors that is based on the site-confined destruction of tumor tissue by multiple short,high-intensity electrical pulses.^([1])Currently there is a heated debate about whether the therapy is thermal or non-thermal.The'non-thermal proponents'advocate | Michal Heger Allard C van der Wal Gert Storm Martin J van Gemert | 2015 | Hepatobiliary & Pancreatic Diseases International2015，14，3： | 2 |
| 3 | The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy显示文摘 | Roy van der Meel Marc H. Symons Robert Kudernatsch Robbert J. Kok Raymond M. Schiffelers Gert Storm William M. Gallagher Annette T. Byrne | 2011 | Drug Discovery Today2011，，5： | 1 |
| 4 | Imaging the Efficacy of Anti-Inflammatory Liposomes in a Rabbit Model of Atherosclerosis by Non-Invasive Imaging显示文摘 | Mark E. Lobatto Claudia Calcagno Josbert M. Metselaar Gert Storm Erik S.G. Stroes Zahi A. Fayad Willem J.M. Mulder | 2012 | Methods in Enzymology2012，，： | 1 |
| 5 | Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress显示文摘 | Twan Lammers Fabian Kiessling Wim E. Hennink Gert Storm | 2011 | Journal of Controlled Release2011，，2： | 1 |
| 6 | Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress显示文摘 | Twan Lammers Fabian Kiessling Wim E. Hennink Gert Storm | 2011 | Journal of Controlled Release2011，，2： | 1 |
| 7 | Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity显示文摘 | Ewelina Kluza Sin Yuin Yeo Sophie Schmid Daisy W.J. van der Schaft Renate W. Boekhoven Raymond M. Schiffelers Gert Storm Gustav J. Strijkers Klaas Nicolay | 2010 | Journal of Controlled Release2010，，： | 1 |
| 8 | Duration of ultrasound-mediated enhanced plasma membrane permeability显示文摘 | Bart Lammertink Roel Deckers Gert Storm Chrit Moonen Clemens Bos | 2014 | International Journal of Pharmaceutics2014，，： | 1 |
| 9 | Liposome-Encapsulated Prednisolone Phosphate Inhibits Growth of Established Tumors in Mice显示文摘 | Raymond M. Schiffelers Josbert M. Metselaar Marcel H.A.M. Fens Adri?nne P.C.A. Janssen Grietje Molema Gert Storm | 2005 | Neoplasia2005，，： | 1 |
| 10 | Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice显示文摘 | Manuela Banciu Raymond M. Schiffelers Marcel H.A.M. Fens Josbert M. Metselaar Gert Storm | 2006 | Journal of Controlled Release2006，，： | 1 |
| 11 | Liposomal corticosteroids for the treatment of inflammatory disorders and cancer显示文摘 | Burcin Ozbakir Bart J. Crielaard Josbert M. Metselaar Gert Storm Twan Lammers | 2014 | Journal of Controlled Release2014，，： | 1 |
| 12 | LIGAND-TARGETED LIPOSOMES DIRECTED AGAINST PATHOLOGICAL VASCULATURE显示文摘 | Raymond M. Schiffelers Grietje Molema Timo L. M. ten Hagen Adri?nne P. C. A. Janssen Astrid J. Schraa Robbert J. Kok Gerben A. Koning Gert Storm | 2002 | Journal of Liposome Research (-)2002，，1： | 1 |
| 13 | In situ gelling hydrogels for pharmaceutical and biomedical applications显示文摘 | Sophie R. Van Tomme Gert Storm Wim E. Hennink | 2008 | International Journal of Pharmaceutics2008，，1： | 1 |
| 14 | Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release显示文摘 | Chris Oerlemans Wouter Bult Mariska Bos Gert Storm J. Frank W. Nijsen Wim E. Hennink | 2010 | Pharmaceutical Research2010，，： | 1 |
| 15 | In situ gelling hydrogels for pharmaceutical and biomedical applications 显示文摘 | van Tomme S R Storm Gert Hennink W E | 2008 | Int JPharm2008，355，12： | 1 |
| 16 | Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment显示文摘 | Roy van der Meel Sabrina Oliveira Isil Altintas Rob Haselberg Joris van der Veeken Rob C. Roovers Paul M.P. van Bergen en Henegouwen Gert Storm Wim E. Hennink Raymond M. Schiffelers Robbert J. Kok | 2011 | Journal of Controlled Release2011，，2： | 1 |
| 17 | Cancer nanomedicine meets immunotherapy:opportunities and challenges显示文摘Cancer nanomedicines have shown promise in combination immunotherapy,thus far mostly preclinically but also already in clinical trials.Combining nanomedicines with immunotherapy aims to reinforce the cancer-immunity cycle,via potentiating key steps in the immune reaction cascade,namely antigen release,antigen processing,antigen presentation,and immune cell-mediated killing.Combination nano-immunotherapy can be realized via three targeting strategies,i.e.,by targeting cancer cells,targeting the tumor immune microenvironment,and targeting the peripheral immune system.The clinical potential of nano-immunotherapy has recently been demonstrated in a phase III trial in which nano-albumin paclitaxel(Abraxane■)was combined with atezolizumab(Tecentriq■)for the treatment of patients suffering from advanced triple-negative breast cancer.In the present paper,besides strategies and initial(pre)clinical success stories,we also discuss several key challenges in nano-immunotherapy.Taken together,nanomedicines combined with immunotherapy are gaining significant attention,and it is anticipated that they will play an increasingly important role in clinical cancer therapy. | Qingxue Sun Xiangyang Bai Alexandros Marios Sofias Roy van der Meel Eduardo Ruiz-Hernandez Gert Storm Wim EHennink Bruno De Geest Fabian Kiessling Hai-jun Yu Twan Lammers Yang Shi | 2020 | Acta Pharmacologica Sinica2020，41，7： | 0 |
| 18 | Role of spleen tyrosine kinase in liver diseases显示文摘Spleen tyrosine kinase (SYK),a non-receptor tyrosine kinase,is expressed in most hematopoietic cells and non-hematopoietic cells and play a crucial role in both immune and non-immune biological responses.SYK mediate diverse cellular responses via an immune-receptor tyrosine-based activation motifs (ITAMs)-dependent signalling pathways,ITAMs-independent and ITAMs-semidependent signalling pathways.In liver,SYK expression has been observed in parenchymal (hepatocytes) and non-parenchymal cells (hepatic stellate cells and Kupffer cells) and found to be positively correlated with the disease severity.The implication of SYK pathway has been reported in different liver diseases including liver fibrosis,viral hepatitis,alcoholic liver disease,non-alcoholic steatohepatitis and hepatocellular carcinoma.Antagonism of SYK pathway using kinase inhibitors have shown to attenuate the progression of liver diseases thereby suggesting SYK as a highly promising therapeutic target.This review summarizes the current understanding of SYK and its therapeutic implication in liver diseases. | Dhadhang Wahyu Kurniawan Gert Storm Jai Prakash Ruchi Bansal | 2020 | World Journal of Gastroenterology2020，26，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员